Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Insights from 2023 ESMO Annual Meeting
A

ESMO 2023 Insights: "Durable Efficacy of Zenocutuzumab, a HER2 x HER3 Bispecific Antibody, in Advanced NRG1+ NSCLC"

By Insights from 2023 ESMO Annual Meeting FEATURING Alison Schram
By Insights from 2023 ESMO Annual Meeting FEATURING Alison Schram
78 views
November 24, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Lung
14:26
Memorial Sloan Kettering Cancer Center

Radiation for Unresectable NSCLC: Where Are We Now and Where Are We …

Feat. D. Gomez
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
14:52
Memorial Sloan Kettering Cancer Center

Advances in Resectable NSCLC

Feat. K. Gray
09:38
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "CDC7 Inhibition Constrains Lineage Plastic…

Feat. A. Quintanal-Villalonga
06:04
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "Durable Efficacy of Zenocutuzumab, a HER2 …

Feat. A. Schram
14:02
Insights from 2023 WCLC

WCLC 2023 Insights: "MSI and MMR-D Define a Distinct Subset of …

Feat. S. Yang
10:18
i3 Health

Additional Advances in Squamous NSCLC Research and Clinical Trials

Feat. M. Kris
08:03
i3 Health

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertio…

Feat. H. Yu, M. Arcila
10:16
Memorial Sloan Kettering Cancer Center

2021 ASCO Updates on KEYLYNK-013 Study for Newly Diagnosed LS-SCLC: …

Feat. A. Rimner
05:59
Memorial Sloan Kettering Cancer Center

2021 ASCO Updates on METex14 Skipping mNSCLC: ctDNA Dynamics & R…

Feat. P. Paik
20:40
Memorial Sloan Kettering Cancer Center

Can TTFields with Chemotherapy Improve Clinical Outcome in the First…

Feat. C. Simone II
17:52
Memorial Sloan Kettering Cancer Center

Malignant Pleural Mesothelioma: What Do Clinical Trials Suggest on A…

Feat. M. Zauderer
16:53
Memorial Sloan Kettering Cancer Center

Should We Combine EGFR TKIs With Upfront Radiation Therapy in EGFR+ …

Feat. K. Beal
21:24
GRACE

Is There a Role for IO in EGFR+ Metastatic Lung Cancer?

Feat. H. Yu
19:58
Beacon Medical Interchange

Current Practice & Challenges in Execution of Genomic Testing in…

Feat. J. West, G. Riely
28:12
Beacon Medical Interchange

Should Local Ablation Therapy in Oligometastatic or Oligoprogressing…

Feat. J. West, G. Riely
23:26
CancerGRACE

EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

Feat. H. Yu
09:30
GRACE

Q&A on EGFR Initial Treatment and Acquired Resistance in Advance…

Feat. H. Yu
07:39
Nebraska Oncology Society

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III T…

Feat. G. Riely
16:08
Nebraska Oncology Society

Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemo…

Feat. G. Riely